References
1 Bejiqi R, Retkoceri R, Maloku A, Mustafa A, Bejiqi H, Bejiqi R. The
Diagnostic and Clinical Approach to Pediatric Myocarditis: A Review of
the Current Literature. Open Access Maced J Med Sci 2019; 7: 162-173.
2 Niu L, An XJ, Tian J, Wang Y. 124 cases of clinical analysis of
children with viral myocarditis. Eur Rev Med Pharmacol Sci 2015; 19:
2856-9.
3 Gabr RE, El-Sharkawy AM, Schär M, Weiss RG, Bottomley PA. High-energy
phosphate transfer in human muscle: diffusion of phosphocreatine. Am J
Physiol Cell Physiol 2011; 301: 234-41.
4 Wallimann T, Tokarska-Schlattner M, Schlattner U. The creatine kinase
system and pleiotropic effects of creatine. Amino Acids 2011; 40:
1271-96.
5 Neubauer S. The failing heart–an engine out of fuel. N Engl J Med
2007; 356: 1140-51.
6 Kôrge P, Silber ML, Gollnick PD. Effect of creatine phosphate on the
contractile activity in acutely failing rat heart. Cardiologia 1998; 43:
1345-54.
7 Saks VA, Dzhaliashvili IV, Konorev EA, Strumia E. Molecular and
cellular aspects of the cardioprotective mechanism of phosphocreatine.
Biokhimiia 1992; 57: 1763-84.
8 Sharov VG, Afonskaya NI, Ruda MY, Cherpachenko NM, Pozin EYa,
Markosyan RA, et al . Protection of ischemic myocardium by
exogenous phosphocreatine (neoton): pharmacokinetics of phosphocreatine,
reduction of infarct size, stabilization of sarcolemma of ischemic
cardiomyocytes, and antithrombotic action. Biochem Med Metab Biol 1986;
35: 101-14.
9 Strumia E, Pelliccia F, D’Ambrosio G. Creatine phosphate:
pharmacological and clinical perspectives. Adv Ther 2012; 29: 99-123.
10 Xu L, Wang CY, Lv L, Liu KX, Sun HJ, Han GZ. Pharmacokinetics of
phosphocreatine and its active metabolite creatine in the mouse plasma
and myocardium. Pharmacol Rep 2014; 66: 908-14.
11 Lorenzi E, Piacenza G, Strumia E, Borgoglio R. Pharmacokinetics of
phosphocreatine following intravenous administration in humans and
effect on blood levels of ATP. Cardiologia 1987; 32: 1031-4.
12 Afonskaia NI, Shepeleva II, Aniukhovskiĭ EP, Samarenko MB, Makhotina
LA. Pharmacokinetics of phosphocreatine in the blood serum of man, dogs
and rabbits. Biull Eksp Biol Med 1985; 100: 591-3.
13 Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA. New
equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009;
20: 629-37.
14 Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A. A simple estimate
of glomerular filtration rate in children derived from body length and
plasma creatinine. Pediatrics 1976; 58: 259-63.
15 Sun N, Li Q, Zhao L, He H, Zhang M, Wang X. Simultaneous quantitative
analysis of phosphocreatine, creatine and creatinine in plasma of
children by HPLC-MS/MS method: Application to a pharmacokinetic study in
children with viral myocarditis. Biomed Chromatogr 2019; 33: e4558.
16 Patel YT, Daryani VM, Patel P, Zhou D, Fangusaro J, Carlile DJ.
Population Pharmacokinetics of Selumetinib and Its Metabolite
N-desmethyl-selumetinib in Adult Patients With Advanced Solid Tumors and
Children With Low-Grade Gliomas. CPT Pharmacometrics Syst Pharmacol
2017; 6: 305-314.
17 Beal SL. Ways to fit a PK model with some data below the
quantification limit. J Pharmacokinet Pharmacodyn 2001; 28: 481-504.
18 Hazendonk H, Fijnvandraat K, Lock J, Driessens M, van der Meer F,
Meijer K, et al . A population pharmacokinetic model for
perioperative dosing of factor VIII in hemophilia A patients.
Haematologica 2016; 101: 1159-1169.
19 Björkman S, Folkesson A, Jönsson S. Pharmacokinetics and dose
requirements of factor VIII over the age range 3-74 years: a population
analysis based on 50 patients with long-term prophylactic treatment for
haemophilia A. Eur J Clin Pharmacol 2009; 65: 989-98.
20 Persky AM, Brazeau GA, Hochhaus G. Pharmacokinetics of the dietary
supplement creatine. Clin Pharmacokinet 2003; 42: 557-574.